Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
4.95
Dollar change
-0.74
Percentage change
-13.01
%
Feb 13, 2:52 AMCVRx posts Q4 2025 results (revenue $16.0M, net loss $0.46/share), reports modest growth but guides to reacceleration as its sales force matures, and launches the BENEFIT‑HF randomized trial with CMS Category B IDE coverage targeting ~2,500 patients—potentially tripling its Barostim heart‑failure market opportunity to ~$30B with an estimated $20–30M net cash impact over 5–7 years.
IndexRUT P/E- EPS (ttm)-2.04 Insider Own39.76% Shs Outstand26.31M Perf Week-24.43%
Market Cap129.74M Forward P/E- EPS next Y-1.82 Insider Trans-0.60% Shs Float15.79M Perf Month-18.18%
Enterprise Value104.53M PEG- EPS next Q-0.53 Inst Own30.80% Short Float10.40% Perf Quarter-48.00%
Income-53.31M P/S2.29 EPS this Y0.49% Inst Trans-3.25% Short Ratio6.07 Perf Half Y-31.63%
Sales56.65M P/B3.31 EPS next Y10.27% ROA-44.76% Short Interest1.64M Perf YTD-30.28%
Book/sh1.49 P/C1.71 EPS next 5Y6.41% ROE-96.59% 52W High15.41 -67.89% Perf Year-65.84%
Cash/sh2.89 P/FCF- EPS past 3/5Y-0.43% -22.44% ROIC-59.58% 52W Low4.30 15.14% Perf 3Y-71.34%
Dividend Est.- EV/EBITDA- Sales past 3/5Y36.11% 56.40% Gross Margin83.99% Volatility10.73% 10.71% Perf 5Y-
Dividend TTM- EV/Sales1.85 EPS Y/Y TTM24.27% Oper. Margin-90.49% ATR (14)0.63 Perf 10Y-
Dividend Ex-Date- Quick Ratio6.72 Sales Y/Y TTM10.45% Profit Margin-94.10% RSI (14)28.21 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio7.63 EPS Q/Q-5.64% SMA20-24.17% Beta1.31 Target Price10.80
Payout- Debt/Eq1.28 Sales Q/Q4.45% SMA50-32.34% Rel Volume2.59 Prev Close5.69
Employees223 LT Debt/Eq1.28 EarningsFeb 12 AMC SMA200-35.60% Avg Volume270.76K Price4.95
IPOJun 30, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-4.88% 1.56% Trades Volume701,788 Change-13.01%
Date Action Analyst Rating Change Price Target Change
May-09-25Downgrade JP Morgan Neutral → Underweight $7
Jan-14-25Upgrade William Blair Mkt Perform → Outperform
Sep-10-24Initiated Cantor Fitzgerald Overweight $14
Jul-11-24Reiterated Lake Street Buy $18 → $12
May-01-24Resumed Craig Hallum Buy $30 → $23
May-01-24Downgrade William Blair Outperform → Mkt Perform
May-01-24Downgrade JP Morgan Overweight → Neutral $36 → $13
Jan-31-23Initiated Lake Street Buy $20
Jul-18-22Initiated Craig Hallum Buy $15
Jul-26-21Initiated William Blair Outperform
Feb-13-26 08:30AM
Feb-12-26 06:19PM
05:30PM
04:28PM
04:05PM
07:35AM Loading…
Feb-11-26 07:35AM
Jan-29-26 04:10PM
Jan-23-26 12:33PM
Jan-22-26 04:05PM
Jan-12-26 08:00AM
Jan-06-26 08:30AM
Dec-22-25 08:30AM
Nov-19-25 08:30AM
Nov-06-25 12:03AM
Nov-05-25 07:10PM
06:06PM Loading…
06:06PM
04:05PM
Nov-04-25 08:37AM
08:30AM
Oct-22-25 04:30PM
Aug-05-25 03:04AM
Aug-04-25 05:20PM
04:16PM
04:05PM
Jul-30-25 10:00AM
Jul-29-25 08:30AM
Jul-28-25 10:00AM
Jul-21-25 04:30PM
Jul-17-25 04:58AM
Jul-16-25 07:30AM
04:30PM Loading…
May-28-25 04:30PM
May-09-25 03:40AM
May-08-25 06:35PM
05:27PM
04:05PM
May-07-25 11:20AM
May-06-25 10:00AM
May-01-25 10:01AM
Apr-24-25 04:30PM
Apr-09-25 08:45AM
Apr-07-25 04:05PM
Feb-12-25 02:45PM
Feb-11-25 09:55AM
Feb-07-25 09:55AM
Feb-05-25 02:14AM
Feb-04-25 05:45PM
04:49PM
04:05PM
Feb-03-25 07:08AM
Jan-21-25 04:30PM
Jan-16-25 10:00AM
Jan-13-25 08:00AM
Dec-23-24 04:30PM
Nov-26-24 08:31AM
Nov-20-24 04:30PM
Nov-04-24 08:00AM
Oct-30-24 03:14AM
Oct-29-24 05:50PM
04:46PM
04:05PM
Oct-28-24 09:08AM
Oct-21-24 08:42AM
06:40AM
Oct-19-24 02:10PM
Oct-18-24 02:08PM
Oct-15-24 04:30PM
Sep-12-24 10:13AM
08:00AM
Sep-03-24 08:30AM
Aug-26-24 09:00PM
Aug-05-24 07:22PM
05:20PM
Aug-02-24 08:00AM
Jul-31-24 04:27PM
Jul-29-24 05:40PM
04:38PM
04:05PM
Jul-15-24 04:30PM
Jul-12-24 11:54AM
Jun-25-24 06:50AM
Jun-06-24 05:48AM
May-22-24 08:30AM
May-16-24 07:30AM
May-01-24 10:45AM
08:39AM
07:42AM
07:31AM
Apr-30-24 08:56PM
05:44PM
04:34PM
04:05PM
Apr-19-24 11:14AM
Apr-16-24 04:30PM
Apr-15-24 07:30AM
Jan-31-24 08:00AM
Jan-27-24 11:10AM
Jan-26-24 07:14AM
Jan-25-24 05:45PM
04:50PM
04:39PM
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON & JOHNSON10% OwnerNov 26 '25Sale10.036,33763,5604,040,861Dec 01 04:07 PM
JOHNSON & JOHNSON10% OwnerNov 24 '25Sale10.062,20022,1324,047,198Nov 25 12:54 PM
JOHNSON & JOHNSON10% OwnerNov 21 '25Sale10.005005,0004,049,398Nov 25 12:54 PM
JOHNSON & JOHNSON10% OwnerNov 12 '25Sale10.001,00010,0004,049,898Nov 14 03:07 PM
JOHNSON & JOHNSON10% OwnerNov 06 '25Sale10.2152,332534,3104,051,098Nov 10 03:28 PM
JOHNSON & JOHNSON10% OwnerNov 07 '25Sale10.002002,0004,050,898Nov 10 03:28 PM
Nielsen Kirk G.DirectorMay 15 '25Buy5.4510,96659,7951,910,134May 19 06:46 PM
Nielsen Kirk G.DirectorMay 13 '25Buy5.29101,413536,3131,837,968May 14 05:27 PM
Nielsen Kirk G.DirectorMay 14 '25Buy5.2361,200320,3641,899,168May 14 05:27 PM
Nielsen Kirk G.DirectorMay 12 '25Buy4.7925,200120,6701,736,555May 14 05:27 PM
Jain Mudit K.DirectorMay 12 '25Buy4.661,5006,9864,900May 13 07:12 PM
Jain Mudit K.DirectorMay 13 '25Buy5.261507895,050May 13 07:12 PM
Hykes KevinPRES & CEOMay 12 '25Buy4.845,00024,200133,000May 12 07:07 PM